Robert Hariri

Company: Celularity

Job title: CEO

Seminars:

Preclinical and Clinical Development of Human Placental Hematopoietic Stem Cell Derived NK Cells (CYNK001) for the Treatment of COVID-19 4:20 pm

• Celularity has developed a novel proprietary GMP procedure that enables the scalable production of an off-the-shelf, allogeneic NK cell therapy (CYNK-001) • Combining pathogenic mechanism of coronavirus, existing and validated research results, we hypothesize adoptive CYNK001 therapy may provide the antiviral activities thereby serve as effective solutions for COVID-19 patients • Discuss the initial…Read more

day: Day Two